

1st Sub. H.B. 399

OPIOID ABUSE PREVENTION AND TREATMENT AMENDMENTS

SENATE COMMITTEE AMENDMENTS

AMENDMENT 2

MARCH 5, 2018 1:00 PM

Representative **Steve Eliason** proposes the following amendments:

1. *Page 1, Line 18:*

18 ~~{None}~~ **This bill appropriate in fiscal year 2019:**
 ► to the Department of Health - Division of Division of Disease Control and Prevention, as a one-time
 appropriation:
 • from the General Fund, One-time, \$9,300.

2. *Page 2, Line 30:*

30 (1) ~~{The}~~ **As funding is available, the** department shall produce and distribute, in
 conjunction with the Division of

3. *Page 3, Lines 69 through 70:*

69 (5) (a) A pharmacist who sells or dispenses a Schedule II or Schedule III controlled
70 substance that is an opiate shall **, if available from the Department of Health,** prominently display at the
 point of sale the informational

4. *Page 3, Line 74*

House Committee Amendments

2-27-2018:

74 taking opiates.

(c) The requirement in Subsection (5)(a) does not apply to a pharmacist if the pharmacist is unable to
obtain the informational pamphlet from the Department of Health for any reason.

5. *Page 3, Line 84*

House Committee Amendments

2-27-2018:

84 container with the label attached.

Section 3. Appropriation.
The following sums of money are appropriated for the fiscal year beginning July 1, 2018, and ending
June 30, 2019. These are additions to amounts previously appropriated for fiscal year 2019. Under the
terms and conditions of Title 63J, Chapter 1, Budgetary Procedures Act, the Legislature appropriates
the following sums of money from the funds or accounts indicated for the use and support of the

government of the state of Utah.

ITEM 1

To Department of Health – Division of Disease Control and Prevention

From General Fund, One-time

\$9,300

Schedule of Programs:

Health Promotion

\$9,300

The Legislature intends that the Division of Disease Control and Prevention expend appropriations provided under this item to print, produce, and distribute the informational pamphlet described in Section 26-55-109 and the warning label described in Section 58-37-7.